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2Abstract
There are well-established approaches for osteogenic differentiation of embryonic stem cells
(ESCs), but few show direct comparison with primary osteoblasts or demonstrate differences
in response to external factors. Here, we show comparative analysis of in vitro osteogenic
differentiation of mouse ESC (osteo-mESC) and mouse primary osteoblasts. Both cell types
formed mineralized bone nodules and produced osteogenic extracellular matrix (ECM), based
on immunostaining for osteopontin and osteocalcin. However, there were marked differences
in the morphology of osteo-mESCs and levels of mRNA expression for osteogenic genes. In
response to addition of ‘proinflammatory’ cytokines interleukin 1-β (IL-1β), tumor necrosis 
factor-α (TNF-α) and interferon-γ (IFN-γ) to the culture medium, primary osteoblasts showed 
increased production of nitric oxide (NO) and prostaglandin E2 (PGE2) at early timepoints and
decreases in cell viability. In contrast, osteo-mESCs maintained viability and did not produce
NO and PGE2 until day 21. The formation of bone nodules by primary osteoblasts was reduced
markedly after cytokine stimulation, but was unaffected in osteo-mESCs. Cell sorting of osteo-
mESCs by cadherin-11 (cad-11) showed clear osteogenesis of cad-11+ cells, compared to
unsorted osteo-mESCs and cad-11- cells. Moreover, the cad-11+ cells showed a significant
response to cytokines, similar to primary osteoblasts. Overall, these results show that while
osteo-mESC cultures, without specific cell sorting, show characteristics of osteoblasts, there
are also marked differences, notably in their responses to cytokine stimuli. These findings are
relevant to understanding differentiation of stem cells and especially developing in vitro models
of disease, testing new drugs and developing cell therapies.
3Introduction
Demand for new treatments for skeletal diseases such as arthritis, osteoporosis and non-union
fractures has grown, as the global population expands and the proportion of elderly people
increases [1]. Regenerative medicine aims to provide a solution to these disorders; tissue
engineered constructs have the potential to act as bone grafts, with the establishment of a cell
population seeded within a construct. Osteogenic cells differentiated from embryonic stem cells
(ESCs) show promise for this objective and for the purposes of in vitro disease modeling [2-5].
A major challenge of utilizing ESCs for regenerative medicine purposes is the directed and
reproducible differentiation of the cells down an osteogenic lineage, to the exclusion of other
cell types.
In vivo, bone development is highly regulated and results in an organized and hierarchically
ordered structure [6]. Bone development progresses through distinct developmental stages
starting with the commitment of mesenchymal stem cells (MSCs) to the osteoblast lineage,
proliferation of osteoprogenitors and maturity of the differentiated osteoblast, leading to the
formation of mineralized extracellular matrix (ECM) [7]. To produce osteoblasts effectively
from ESCs, this progression needs to be followed in vitro.
In vitro differentiation of osteoblasts results in the formation of distinct colonies of mineralized
bone-like matrix, known as bone nodules [8,9]. The ECM deposited by osteoblasts in vitro has
been shown to include collagen-I (col-I), fibronectin, osteocalcin (OCN) and osteopontin
(OPN), and staining for these proteins is often most predominant around the mineralized
nodules [10-13]. The process of osteogenesis is coordinated by various transcription factors,
with Runx2 and osterix being regarded as key regulators [14-16].
4Both mouse [17,18] and human ESCs [19-21] have been shown to display the features of
osteogenically differentiated cells in vitro, exhibiting molecular and structural features
resembling bone tissue by the formation of mineralized bone nodule structures. The majority
of osteogenic protocols for ESCs direct cell differentiation by including factors in the culture
medium, such as β-glycerophosphate (BGP), ascorbate, dexamethasone, simvastatin, retinoic 
acid, vitamin D3 and bone morphogenic proteins (BMPs) [3,22-30]. Although, ‘traditional’
osteogenic differentiation strategies for ESCs, leads to the formation of bone nodules and
expression of osteogenic markers, little research has compared this to the in vitro differentiation
of osteoblasts.
Osteogenic differentiation is often shown by the presence of osteogenic markers, but it is also
useful to explore the functional biochemical response of the cells to certain stimuli, in
comparison to osteoblasts. In this study, we examine the responses of the cells to cytokines
associated with inflammation, including, interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-
α) and interferon-γ (IFN-γ).  These proinflammatory cytokines are proteins that co-ordinate 
local and systemic inflammation and have in vitro effects on osteoblast proliferation, collagen
synthesis, mineralization and ALP activity [31-35]. Responses to proinflammatory
environments can be measured by increased prostaglandin E2 (PGE2) and nitric oxide (NO),
changes in cell viability and expression of inducible enzymes [36,37]. The response of
osteoblasts to proinflammatory cytokines has been investigated extensively [31-38], whereas
little work has been performed on ESC-derived osteogenic cells. The impact of inflammation
in osteogenic differentiation may also be of some importance when producing a potential cell
therapy. A regenerative medicine product would be manufactured under favorable conditions,
5supporting cell growth and viability. Subsequently subjecting it to a damaged/diseased
environment could have a significant effect on the success or failure of the final therapy.
To progress ESCs to use in cell therapies and regenerative medicine, differentiation needs to be
fully validated, and it is likely that a cell selection step will be required to isolate the purified
cell population of interest. Currently, there is no commonly used cell surface marker of the early
osteoblast for cell sorting. In this study, we investigate cadherin-11 (cad-11) as a marker for the
purification of osteogenically differentiated ESCs. Cad-11 has previously been used to purify
ESCs [18], and is a cell adhesion molecule strongly associated with bone formation and
osteogenic differentiation [39,40].
In this study, we compare the osteogenic differentiation of mouse ESC (mESC) with mouse
primary osteoblasts, and subsequently study the differentiation of a subpopulation of ESC
selected for cad-11 expression. We describe significant differences in the osteogenic
differentiation of the cell types and show significant differences in responses of the cell types
to exposure to the proinflammatory cytokines interleukin-1β (IL-1β), tumor necrosis factor-α 
(TNF-α) and interferon-γ (IFN-γ).  
Materials and Methods
Cell Culture
Mouse embryonic stem cells (CEE line [41]) were cultured on a monolayer of mitotically
inactivated mouse fibroblasts (SNL line), as previously described [42]. Cells were maintained
6in Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen, Paisley, UK) containing 10%
fetal bovine serum (FBS, Biosera, East Sussex, UK), 100 U/mL penicillin and 100 μg/mL 
streptomycin (Sigma, Poole, UK), 2 mM L-Glutamine (Sigma), 500 μM β-Mercaptoethanol 
(Sigma) and 500 U/mL leukemia inhibitory factor (LIF, Millipore, Watford, UK).
Primary calvarial osteoblasts were obtained from 1-3 day old CD1 mouse calvaria by sequential
enzymatic digestion. Calvaria were dissected and digested in a solution of 1.4 mg/mL
collagenase type IA (Sigma) and 0.5 mg/mL trypsin II S (Sigma). Cells released during the first
2 populations (10 minute digestions) were discarded, and populations of cells from the next 3
digestions (20 minute digestions) were plated in tissue culture flasks at a density of 6.6 x 103
cells/cm2. Cells were cultured in minimum essential medium-α (αMEM, Lonza, Belgium), 
containing 10% FBS (Sigma), 100 U/mL penicillin and 100 μg/mL streptomycin and 2 mM L-
Glutamine. For osteogenic differentiation, cells were plated at a density of 10,600 cells/cm2,
allowed to adhere overnight, and medium supplemented with 50 mM BGP (Sigma), 50 μg/mL 
ascorbate 2-phosphate (Sigma) and at points when proinflammatory cytokines were not present,
10 μM dexamethasone (Sigma).  
Osteogenic Differentiation of mESCs
Embryoid bodies (EBs) were formed from mESCs by mass suspension, in mESC culture
medium without LIF for 3 days. Trypsin-mediated dissociation of EBs, yielded a single cell
suspension that was plated at a density of 10,600 cells/cm2 in 0.1% (w/v) gelatin-coated well-
plates. Osteogenic differentiation was induced by supplementing medium with 50 mM BGP,
50 μg/mL ascorbate 2-phosphate and at points when proinflammatory cytokines were not 
7present, 10 μM dexamethasone. From this point forward, mESCs were referred to as osteo-
mESCs and treated identically to primary osteoblasts.
Alizarin Red S Staining
Cell monolayers were fixed in 10% (v/v) formalin and stained for the presence of calcified
matrix using a 2% (w/v) solution of alizarin red S (Sigma, pH 4.2) for 4 minutes at room
temperature. Images were taken with a Nikon Eclipse 90i stereo dissection microscope or Nikon
Eclipse TS100 inverted microscope with Hoffman contrast. Image analysis and quantification
of area stained was performed using ImageJ version 1.43U (NIH, USA).
Immunocytochemistry
Cell culture plates were fixed with a 4% solution of paraformaldehyde (Sigma) for 20 minutes.
After washing with PBS cells were permeabilized with 0.1% (v/v) Triton X-100 (Sigma) for 45
minutes and washed with PBS. After blocking nonspecific binding by incubating in 3% donkey
serum (Sigma) for 20 minutes, cells were incubated with primary antibodies at 4°C overnight.
After washing with PBS, cells were incubated with secondary antibodies (donkey Alexa-Fluor-
488 or 546, Invitrogen) for 1 hour at room temperature. Nuclear counterstaining with Hoechst
33258 was performed. Details of antibodies can be found in supplementary information Table
S1. Fluorescent images were captured and processed using a Leica DM-IRB, inverted
microscope and Volocity imaging software (Improvision, Coventry, UK).
8Real-time quantitative polymerase chain reaction (RT-qPCR)
RNA was extracted using an RNeasy kit (Qiagen, West Sussex, UK) according to
manufacturer’s instructions. Reverse transcription of 400 ng RNA into single stranded cDNA
was performed using the superscript II system (Invitrogen), according to manufacturer’s
instructions. RT-qPCR was performed on a MyiQ RT-PCR detection system (Bio-Rad, Ontario,
Canada) with iQ SYBR Green supermix (Bio-Rad). Efficiency and CT calculations performed
using online software based on a four parameter simple exponent model [43]. Expression levels
were calculated using an efficiency-corrected comparative threshold cycle (CT) method (EΔΔCT).
All values were normalized to the Rpl32 ribosomal protein gene. Primer sequences were as
follows: Rpl32 (Fwd) TTAAGCGAAACTGGCGGAAAC, (Rvs)
TTGTTGCTCCCATAACCGATG; Runx2 (Fwd) TGTTCTCTGATCGCCTCAGTG, (Rvs)
CCTGGGATCTGTAATCTGACTCT; Col1a1 (Fwd) GCTCCTCTTAGGGGCCACT, (Rvs)
CCACGTCTCACCATTGGGG; Opn (Fwd) AGCAAGAAACTCTTCCAAGCAA, (Rvs)
GTGAGATTCGTCAGATTCATCCG; Ocn (Fwd) CTGACCTCACAGATGCCAAGC, (Rvs)
TGGTCTGATAGCTCGTCACAAG.
Proinflammatory Cytokine Treatment
Recombinant human IL-1β, human TNF-α and mouse IFN-γ (R&D Systems), were added to 
the culture medium at a concentration of 1 ng/mL, 10 ng/mL and 100 ng/mL respectively,
unless otherwise stated. IL-1β and TNF-α have cross species reactivity between mouse and 
human, IFN-γ does not possess this property. Due to the anti-inflammatory properties of 
9dexamethasone, this was removed from osteogenic medium when the proinflammatory
cytokines were present.
Nitrite and Prostaglandin E2 Production
Nitrite and PGE2 in culture medium was measured after 48 hours proinflammatory cytokine
treatment at various stages of osteogenic culture. Nitrite was measured as an estimation of NO
production, using the Griess Reagent System (Promega, Southampton, UK) according to the
manufacturer’s protocol. Briefly, 50 μL of sample was transferred to a 96-well plate, 50 μL of 
1% sulphanilamide added and incubated for 5 minutes at room temperature, before 50 μL 0.1% 
N-(1-naphthyl)ethylenediamine (NED) added and incubated at room temperature. Absorbance
was measured at 540 nm, with correction at 690 nm, using a plate reader (TECAN Infinite 200
PRO). Concentration calculated from standard curve.
PGE2 concentration within culture medium was determined by enzyme immunoassay (EIA)
using a commercially available kit (Parameter™ PGE2 Assay, R&D Systems), according to the
manufacturer’s protocol. Briefly, a competitive binding EIA was performed on the 3-fold
diluted samples. Optical absorbance was read at 450 nm with correction at 570 nm. PGE2 in the
sample was determined using standard curves. Both nitrite and PGE2 values were corrected for
DNA content of formalin fixed cells, determined by fluorescent Hoechst readings, at excitation
wavelength 360 nm and emission wavelength 460 nm.
Cell Viability Assay
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Cells were plated in 96-well plates. A dose response of IL-1β, TNF-α and IFN-γ was performed 
by keeping the cytokines at a ratio of 1:10:100, but performing a serial dilution to lower the
total dose. Measurements of viability were taken using the CellTiter 96® AQueous One
Solution Cell Proliferation Assay (MTS assay, Promega, Southampton, UK) at certain
timepoints, as per the manufacturer’s protocol. Briefly, 20 μL MTS reagent was added to each 
cell-containing well, in 100 μL culture medium. Cells were incubated at 37°C for 1 hour before 
absorbance read at 490 nm with wavelength correction at 690 nm.
Alkaline Phosphatase Assay
After osteogenic culture, cell monolayers were lysed in a solution of 0.1 % (v/v) Triton X-100
in 0.2 M tris buffer and cell layer collected using a cell scraper. Samples were centrifuged at
10,000 x g for 10 minutes and transferred to a 96-well plate. ALP activity was assessed by
addition of 1 mg/mL p-nitrophenyl phosphate (pNPP) solution in 0.2 M tris buffer (Sigma)..
After 20 minutes incubation at room temperature optical absorbance was read at 405 nm. ALP
concentration was determined from a standard curve.
Magnetic-Activated Cell Sorting (MACS)
Osteo-mESCs were cultured on gelatin-coated flasks in osteogenic medium for 16 days. Cells
were removed from flasks and dissociated by trypsin/EDTA treatment and the cell suspension
passed through a 70 μm cell strainer to remove matrix components. Cells were resuspended in 
cad-11 primary antibody (R&D Systems) at 10 μg/mL for 5 minutes at room temperature, 
incubated in biotinylated secondary antibody (Vector) for 10 minutes at 4°C and finally
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incubated with anti-biotin magnetic microbeads (Miltenyi Biotec, Surrey, UK). Cells were
sorted for cad-11 expression using the MiniMACS™ separator in combination with MS
columns (Miltenyi). Both cad-11+ and cad-11- osteo-mESCs were plated at a density of 20,000
cells/cm2 in gelatin-coated well-plates and cultured in osteogenic medium.
Statistical Analysis
Statistical significance between groups was analyzed using PASW Statistics 18.0.3 software.
Two groups were compared by unpaired Student’s T-Test, multiple groups by one-way
ANOVA.
Results
Osteogenic differentiation of mESCs compared to primary osteoblasts.
In vitro osteogenic differentiation of mESCs was compared to the differentiation of mouse
primary osteoblasts (figure 1). After 21 days in osteogenic medium, both cell types showed
formation of specific areas of calcified matrix or bone nodules, revealed by alizarin red staining
(figure 1A). Subjective observation showed nodules were more abundant in osteo-mESC
cultures. Non-osteogenic controls showed little evidence of staining, although some diffuse,
non-specific background staining of the osteo-mESC matrix was present.
Immunocytochemistry at day 28, revealed staining for col-I and cad-11(figure 1B) and OPN
and OCN (figure 1D) within and around bone nodules formed by both cell types. Staining of
OPN and OCN in non-osteogenic medium was minimal. Visually, there were noticeably more
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cells present in osteo-mESC cultures and cells were smaller and more densely packed, as shown
by Hoechst stain.
RT-qPCR analysis of expression of Runx2, Col1a1, Opn and Ocn at day 18 of osteogenic
culture (Figure 1C) demonstrated significantly lower relative expression levels of all four genes
in osteo-mESCs, particularly osteocalcin, which is a late marker of osteogenesis.
Response of osteo-mESCs to proinflammatory cytokine treatment compared to primary
osteoblasts.
Preliminary work was performed investigating the response of the osteo-mESCs and primary
osteoblasts to individual cytokines and different combinations of cytokines. Nitrite
(supplemental figure S1) and PGE2 (supplemental figure S2) release shows that significant
responses were only seen from the primary calvarial cells when 2 or more cytokines were
combined, and were only seen from the osteo-mESCs when 3 cytokines were combined during
the later stages of osteogenic culture. From these results it was decided to use all three cytokines
in combination to achieve the maximum response.
Osteo-mESCs at different time points of culture, and osteoblasts at day 7 were exposed to IL-
1β, TNF-α and IFN-γ by addition to the culture medium for 48 hours. Nitrite (figure 2A), PGE2
(figure 2C) and expression of inducible nitric oxide synthase (iNOS), the enzyme that leads to
NO production and cyclooxygenase-2 (COX-2) and prostaglandin E synthase (PGES), the
enzymes leading to PGE2 (figure 2B) were assessed. In response to cytokines, osteoblasts
produced large amounts of nitrite and PGE2. In comparison, osteo-mESCs did not produce
PGE2 in response to cytokine stimulation until day 14 of osteogenic differentiation. Osteo-
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mESCs did not produce significant concentrations of nitrite, until day 21. In comparison to the
7-day cultured osteoblasts, levels produced were lower at all the time points. To corroborate
nitrite and PGE2 results, staining for iNOS, COX-2 and PGES was performed (figure 2B).
Osteoblasts showed positive staining for iNOS, COX-2 and PGES, in the majority of cells
(figure 2B, a,f,l). Osteo-mESCs did not show any staining for iNOS in response to cytokines
until day 21, and this was clustered around areas of dense nuclear staining. Both COX-2 and
PGES staining was seen when cytokine-treated at day 14 and day 21, in accordance with the
PGE2 results. No staining was seen in unstimulated controls (data not shown).
Changes in cell viability in response to IL-1β, TNF-α and IFN-γ treatment was assessed by 
MTS assay; cells were treated with cytokines continually over a 24-day period at a range of
cytokine concentrations, all with ratio 1:10:100, (IL-1β:TNF-α:IFN-γ, figure 2D and E). 
Primary osteoblasts showed significant reductions in viability at all cytokine concentrations
from the lowest (A: 0.03125 ng/mL IL-1β, 0.3125 ng/mL TNF-α and 3.125 ng/mL IFN-γ) to 
the highest concentration (F: 1 ng/mL IL-1β, 10 ng/mL TNF-α and 100 ng/mL IFN-γ). In 
comparison, osteo-mESCs showed no deleterious changes in cell viability over time, at any
cytokine concentration (figure 2E).
Effect of proinflammatory cytokines on bone nodule formation
To assess the effects short bursts of cytokine stimulation on the osteogenic differentiation of
osteo-mESCs and primary osteoblasts and form bone nodules, cells were stimulated with IL-
1β, TNF-α and IFN-γ at either day 0, day 3, day 7 or day 14 of osteogenic culture for 48 hours, 
before being returned to control osteogenic medium. Alizarin red staining (figure 3A) and
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subsequent quantification of staining (figure 3E and F) demonstrated that the cytokines had
little effect on bone nodule formation of osteo-mESCs, when applied on day 0 or day 3. When
applied on day 7, the proportion of staining relative to the control was significantly higher. In
contrast, when stimulated on day 14, levels of alizarin red staining were significantly lower.
Effects of cytokine stimulation were more apparent in the formation of nodules by primary
osteoblasts. No staining was seen when cells were stimulated on day 0, 3 or 7, and only small
nodules formed after stimulation on day 14, in comparison to unstimulated control.
Phase contrast images of the osteo-mESCs (figure 3B, a-e), showed heterogeneous areas of
cells with considerable matrix production. Images of primary osteoblasts revealed formation of
obvious raised nodules in control cultures (figure 3Bf), that were not present in cells stimulated
on day 0 or 3, and considerably smaller when stimulated on day 7 and day 14.
Immunocytochemistry of OCN, OPN, col-I and cad-11 (figure 3C and D) demonstrated that
short bursts of cytokine stimulation disrupted ECM deposition of the primary osteoblasts at all
the time points. Conversely, osteo-mESCs continued to produce ECM proteins and express cad-
11, in nodular areas, despite cytokine stimulation.
Effect of cad-11 sorting on osteo-mESC differentiation
Osteo-mESCs were cultured until day 16 in osteogenic medium and subsequently sorted based
on expression of cad-11 using MACS. Average percentage of cad-11 positive cells was 21.2%
and numbers were comparable between cell sorting experiments (standard deviation 3.88, n=6).
Cad-11+ and cad-11- cells were cultured in osteogenic medium for up to a further 21 days.
Proinflammatory cytokine stimulation was performed in a “short burst” of 48 hours at day 7
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and day 14 post-sorting, as described previously with non-sorted cells. Alizarin red staining at
21 days (figure 4A), indicated cad-11+ cells formed discrete nodules, similar to the nodules
formed by primary osteoblasts, but appeared unaffected by cytokine stimulation. Cad-11- osteo-
mESCs did not form nodules and only light alizarin red staining, but was also unaffected by
cytokine stimulation. Phase contrast images (figure 4B) further demonstrated that nodules were
formed by cad-11+ cells and revealed the different morphology of the cad-11- cells. Cad-11+
osteo-mESCs stained positive in nodular areas for OCN and OPN (figure 4C, a-c) and col-I
(figure 4D, a-c). Conversely, cad-11- cells did not stain for OPN and lightly stained for OCN
(figure 4 C, d-f). Col-I staining was very sparse (figure 4D, d-f). Staining of neither cad-11+ or
cad-11- osteo-mESCs was affected by the proinflammatory cytokine stimulation, at either
timepoint.
Response of cad-11 sorted osteo-mESCs to proinflammatory cytokines
To assess further differences between cad-11+ and cad-11- osteo-mESCs, response of cells to
IL-1β, TNF-α and IFN-γ, in terms of nitrite production (figure 5A and B), PGE2 production
(figure 5C and D) and expression of iNOS (figure 5E) was assessed at day 7 and day 14 post-
sorting. Both cad-11+ and cad-11- cells produced significant amounts of nitrite and PGE2 in
response to the cytokines at both day 7 and day 14. However, cad-11+ cells produced
significantly more nitrite than cad-11-. This was also reflected in iNOS staining; almost all cad-
11+ cells stained for iNOS, but few cad-11- cells stained positive, suggesting a heterogenous
population. Unstimulated, control cultures did not stain for iNOS, in all cases. Stimulated cad-
11- cells produced significantly more PGE2 at day 7 than cad-11+, but this was also true of the
cad-11- control medium. Production of PGE2 was subsequently reduced by day 14, where it was
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significantly lower than the cad-11+ cells. Levels of nitrite and PGE2 produced in response to
the cytokines were of a similar magnitude to those produced by primary osteoblasts at day 7
(see figure 2).
Discussion
In vitro osteogenic differentiation of primary osteoblasts [8-13,44] and ESCs [17-21] have both
been well described, but there have been few comparative studies. In this study, both cell types
showed expression of markers indicative of osteogenic differentiation and formed nodules
comprising mineralizing matrix. Both cell types stained for proteins associated with osteoblast
differentiation such as OPN, OCN and col-I, particularly associated with the cell colonies/bone
nodules. Expression of the cell-to-cell adhesion molecule cad-11, found in high levels on
osteoblasts, and important in the formation of mesenchymal tissues in embryo development
[45,46], was also seen in both cell types. Despite these similarities, the morphology of the osteo-
mESC cells was noticeably different, showing a heterogeneous population and larger numbers
of nuclei within nodules. Formation of bone nodules within cultures subjectively appeared
different when imaged at both low and high magnification. Despite, the formation of more bone
nodule in the osteo-mESCs, there was a lower expression of osteogenic genes. This can be
explained by non-specific binding of calcium within the osteo-mESC matrix, which may not
be related to osteogenesis.
There is certainly interest in the comparison of osteoblasts derived from primary and stem cell
sources [47-49]. Gentleman et al., (2009) compared mineralized nodules of neonatal mouse
osteoblasts, bone marrow derived-MSCs and mESCs. They concluded that the bone nodules
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formed by mESCs showed distinct differences to those of the osteoblasts and MSCs, in terms
of formation time and Raman spectra of mineral structure [47]. The results of our study support
this, as we saw morphological differences in the formation of bone nodules and expression of
ECM proteins. We also provide additional evidence that mESCs do not have the same responses
to proinflammatory cytokines as primary osteoblasts, indicating a difference in biochemical
response. Although both cell types form bone nodules by day 21, the response of the osteo-
mESCs to cytokine stimulation was very different to that of primary osteoblasts, which showed
reduced cell viability and marked production of nitrite and PGE2, and is consistent with the
literature [37,38,50-55]. In contrast, the osteo-mESCs showed no reductions in cell viability in
response to extended cytokine stimulation nor any significant increases in production of nitrite
or PGE2, until the latter stages of the culture period at day 21; the time point at which traditional
differentiation protocols indicate as fully differentiated. As well as revealing differences
between cells types, investigation of the effects of proinflammatory cytokines on cell response,
particularly ESCs, can give an indication of how cell therapies may perform when subjected to
the environment of disease and inflammation into which they will be implanted. This response
may have a significant bearing on the success or failure of the final therapy.
The effect that short bursts of IL-1β, TNF-α and IFN-γ treatment had on the eventual osteogenic 
differentiation of primary osteoblasts and osteo-mESCs further suggested that the
differentiation process of the ESC is not equivalent to that of primary osteoblasts. The
osteoblasts showed marked responses to the transient exposure of proinflammatory cytokines,
which had knock-on effects on the final differentiation state, with the formation of fewer and
smaller bone nodules. When treated on day 0 or day 3, cell viability fell during the 48 hours in
the presence of the cytokines and continued to fall after returning to osteogenic medium with
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no cytokines, reducing final cell numbers significantly. IL-1β, TNF-α and IFN-γ, have 
previously been shown to cause apoptosis of osteoblasts, particularly when applied in
combination [51,53,56], this may have caused many of the eventual effects seen on cell
differentiation.
Previous reports have focused on the effects of individual cytokines on osteoblast
differentiation; but when used in combination, the effects are synergistic and enhanced [57,58].
IL-1β, TNF-α and IFN-γ, have been shown to inhibit bone nodule formation, decrease ALP 
activity, inhibit OCN and col-I deposition, both in mouse and human osteoblasts [33,35,59-66].
Many of these effects are mediated by NO and PGE2 pathways, which are stimulated by these
cytokines [32,67]. That these effects are not seen with the osteo-mESCs indicates, once again,
the in vitro differentiation process is different to that of primary osteoblasts.
The mechanisms that contribute to the differences in response of the osteo-mESCs to
proinflammatory stimuli remain to be determined, but we can hypothesize that the receptor and
signal transduction pathways may be less developed or less active in mESC-derived osteoblasts.
ESCs and early ES-derived vascular cells have been shown to have a low level of TNF-
receptors and it has been reported that Nuclear Factor-κB, a transcriptional regulator that plays 
a key role in immunity and inflammation, has relatively low expression in undifferentiated ES
cells but increases during differentiation [68,69]. Expression of Toll-like receptors, a group of
receptors associated with the immune and inflammatory response, has also been shown to be
significantly downregulated in hESCs [70].
To investigate further the distinct responses of the different cell types we performed cell-sorting
studies on the ESC cultures. There is no definitive, well-characterized marker of the early
osteoblast. Osteogenesis of ESCs often requires first inducing ES-derived MSCs [71,72], but
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the intention of this study was to avoid the need to perform this step, and directly harvest a
population of osteogenic cells from the mESC cultures. Cad-11 has previously been used to
sort osteogenic cells within differentiating ESC-derived cultures [18]. In our cell sorting
experiments we achieved a cad-11 positive population of about 21%, which was considerably
less than previously described [18]. It is worth noting that during the MACS process, there was
a substantial reduction in the number of cells, and after seeding, many of the cells did not attach
to the plate.
Cad-11+ cells differentiated to osteoblasts as suggested by formation of bone nodules and
immunostaining for OCN, OPN and col-I, similar to primary calvarial cells. The cad-11-
population was more heterogeneous, with little evidence of bone nodule formation or
immunostaining. The advantage of using cad-11, as opposed to a marker such as STRO-1, is
the ability to identify osteoprogenitors, rather than mesenchymal progenitors, and the level of
characterization the cell surface marker has previously received [39,46,73,74].
Differentiation of the cad-11+ mESCs was unaffected by transient exposure to proinflammatory
cytokines, in contrast to primary osteoblasts which responded with reduced cell viability and
nodule formation. This indicates that although comparable to osteogenic differentiation of
primary osteoblasts, the cad-11+ cells were still distinct in biochemical response. However,
unlike the unsorted osteo-mESCs, both cad-11+ and cad-11- cells responded to the presence of
the cytokines by producing NO and PGE2, in similar amounts to the primary calvarial
osteoblasts. It is also interesting to note that at 14 days post-sorting, levels of both NO and PGE2
production, were lower than at 7 days. This decrease in production with progressive
differentiation also occurred with the primary osteoblasts (data not shown). In cad-11+, iNOS
staining was seen in most cells, whereas, in cad-11-cultures iNOS was seen only in a few cells,
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suggesting that a heterogeneous environment. Many cell types, such as fibroblasts and epithelial
cells [75-77], respond to the presence of these cytokines with the production of NO and PGE2,
and it may be that the cad-11- mESCs were differentiated into cells other than the osteoblast.
These results taken together suggest that in sorting for cad-11, a population of ESC-derived
cells that responds more similarly to the early osteoblast was purified.
In this study, we demonstrate that ‘traditional’ protocols for osteogenic differentiation of ESCs
result in significant differences compared to the osteogenic differentiation of primary
osteoblasts. In addition, we show significant differences in the response of osteogenic mESCs
to a proinflammatory environment, when compared to primary osteoblasts, indicating a
dissimilar differentiation state. The findings of this study highlight the need for further
investigation into osteogenic differentiation protocols, particularly a cell-sorting step. We
demonstrated by selecting for cad-11+ cells, comparable osteogenic differentiation, with respect
to primary osteoblasts. In order for osteogenically differentiated ESCs to progress to a clinical
setting, differentiation protocols must be validated and establishment of a pure population of
early osteoblasts must be demonstrated.
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Figure Legends
Figure 1: Osteogenic differentiation of osteo-mESCs and mouse primary calvarial
osteoblasts. (A) Representative images of alizarin red S staining of bone nodule formation by
osteo-mESCs (a,c,e) and primary osteoblasts (b,d,f) in osteogenic (a,b,e,f) and non-osteogenic
medium (c,d) at 21 days culture. Whole-well images of bone nodule formation (scale bar=2
mm) (a,b,c,d). Higher magnification image of osteo-mESC (e) and primary osteoblast (f) bone
nodules in osteogenic medium (scale bar=20 μm).  (B) Immunocytochemistry showing 
expression of col-I (green), cad-11 (red) and nuclei (blue) in bone nodules formed by osteo-
mESCs (a) and primary osteoblasts (b) at day 18 of osteogenic culture (representative images,
scale bar=48 μm). (C) RT-qPCR analysis performed on primary osteoblasts and osteo-mESCs 
at day 18 of culture for osteogenic markers Runx2, Col1a1, Opn and Ocn. Gene expression of
each target gene normalized to Rpl32, and expression of osteo-mESC genes expressed relative
to primary osteoblasts. Data shown mean±SD of 3 independent experiments (n=3). *Statistical
significance of primary osteoblasts vs. osteo-mESCs, p≤0.05. (D) Immunocytochemistry
showing expression of OPN (red) and OCN (green) by osteo-mESCs (a,b,c,g,h,i) and primary
osteoblasts (d,e,f,j,k,l) cultured in osteogenic (a-f) and non-osteogenic (g-l) medium. Merge
image shows OPN and OCN with Hoechst nuclear staining (representative images, scale bar=90
μm). 
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Figure 2: Response of osteo-mESCs to proinflammatory cytokine stimulation compared
to primary osteoblasts. (A and C) Nitrite and PGE2 concentration released into culture
medium, respectively. Osteo-mESCs were treated with IL-β, TNF-α and IFN-γ for 48 hours at 
either day 0, day 7, day 14 or day 21 of osteogenic culture. Primary osteoblasts were treated on
day 7 of culture as a comparator. Nitrite and PGE2 concentrations corrected for DNA content.
Values are mean±SD for three separate experiments each with n=6. Statistical significance vs.
control of same cell type, *p≤0.01. (B) Immunocytochemistry showing inducible enzyme 
expression (iNOS: a-e,scale bar=90 µm; COX-2: f-k, scale bar=46 µm; PGES: l-p, scale bar=46
µm) of primary osteoblasts at day 14 and osteo-mESCs at either day 0, 7, 14 or 21 of osteogenic
culture, in response to 48 hours stimulation with IL-1β, TNF-α and IFN-γ, before fixation. (D 
and E) Dose response effect of proinflammatory cytokines on cell viability of primary
osteoblasts (D) and osteo-mESCs (E). Cells were treated with increasing concentrations of a
combination of IL-1β, TNF-α and IFN-γ over a 24-day time period. Cytokine doses: A (Il-1β 
0.03125 ng/mL, TNF-α 0.3125 ng/mL, IFN-γ 3.125 ng/mL); B (Il-1β 0.0625 ng/mL, TNF-α 
0.625 ng/mL, IFN-γ 6.35 ng/mL); C (Il-1β 0.125 ng/mL, TNF-α 1.25 ng/mL, IFN-γ 12.5 
ng/mL); D (Il-1β 0.25 ng/mL, TNF-α 2.5 ng/mL, IFN-γ 25 ng/mL); E (Il-1β 0.5 ng/mL, TNF-
α 5 ng/mL, IFN-γ 50 ng/mL); F (Il-1β 1 ng/mL, TNF-α 10 ng/mL, IFN-γ 100 ng/mL). Viability 
of cells at certain time points was measured by MTS assay. Data shown as optical absorbance
proportional to cell viability. Values are mean±SD (n=6, experiment repeated in triplicate).
Statistical significance against control *p≤0.05.
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Figure 3: Effect of IL-1β, TNF-α and IFN-γ on bone nodule formation of osteo-mESCs 
and primary osteoblasts. Cells were stimulated at either day 0, 3, 7 or 14 with IL-1β, TNF-α 
and IFN-γ for 48 hours, before being returned to osteogenic medium and cultured continuously 
until either day 14 (alkaline phosphatase) or day 21. (A) Representative images of alizarin red
S staining of calcium deposits in bone nodules formed by osteo-mESCs (a-e) and primary
osteoblasts (f-j). Scale bar=2 mm. (B) Representative phase contrast images of osteo-mESCs
(a-e) and primary osteoblasts (f-j) at day 21. (C) Immunocytochemistry showing OPN (red) and
OCN (green) staining at day 21. Hoechst nuclear counterstain. (D) Immunocytochemistry
showing staining of cad-11 (red) and col-I (green) at day 21. Hoechst nuclear counterstain.
Scale bars for B, C and D at 90 µm. (E and F) Image quantification of alizarin red staining of
osteo-mESCs and primary osteoblasts, respectively. Values corrected to proportion of
osteogenic control. Mean±SD (n=6). (G and H) Alkaline phosphatase activity of osteo-mESCs
and primary osteoblasts, respectively. Values are mean±SD, experiment repeated 3 times, each
with n=6. Statistical significance compared to control **p≤0.01.  
36
37
Figure 4: Osteogenic differentiation of cad-11 sorted osteo-mESCs and effect of
proinflammatory cytokines on bone nodule formation. Cells were sorted for cad-11 at day
16 of osteogenic culture and positive and negative fractions cultured separately in osteogenic
medium. Cells were stimulated with IL-1β, TNF-α and IFN-γ for 48 hours, at day 7 or day 14  
post-sorting before being returned to osteogenic medium and cultured until day 21. (A) Alizarin
red staining of calcium deposits in bone nodules formed by cad-11+ mESCs (a-c) and cad-11-
mESCs (d-f). Scale bar=2 mm, representative images. (B) Phase contrast images of cad-11+
mESCs (a-c) and cad-11- mESCs. (C) Immunocytochemistry showing OPN (red) and OCN
(green) staining of cad-11+ mESCs (a-c) and cad-11- mESCs. (D) Immunocytochemistry
showing col-I staining of cad-11+ mESCs (a-c) and cad-11- mESCs. C and D show Hoechst
nuclear counterstaining, scale bars=46 µm, representative images.
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Figure 5: Response of cad-11 sorted cells to proinflammatory cytokine stimulation. (A and
B) Nitrite concentration in culture medium at day 7 and day 14, respectively, after 48 hours IL-
β, TNF-α and IFN-γ treatment. Values are mean±SD, n=9. Statistical significance of cytokine 
treated versus control, ***p≤0.001. Statistical significance of cad-11- versus cad-11+,
###p≤0.001. (C and D) PGE2 concentration in culture medium at day 7 and day 14, respectively,
after 48 hours IL-β, TNF-α and IFN-γ treatment. Values are mean±SD, n=9. Statistical 
significance of cytokine treated versus control, ***p≤0.001, **p≤0.01. Statistical significance 
of cad-11- versus cad-11+, #p≤0.05. (E) Phase contrast images and immunocytochemistry of 
iNOS expression, in both control cultures (a-d, upper images) and cytokine stimulated (e-h,
lower images) of cad-11+ (a,e,c,g) and cad-11- (b,d,f,h) cultures, at day 7 (a,b,e,f) and day 14
(c,d,g,h) post-sorting. Representative images, scale bar=46 μm. 
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Supplemental Data
Table S1. List of antibody details.
Supporting Information 1
Table S1: List of antibodies
Antigen Source (Catalogue #) Host
Primary
antibodies
Collagen-1 Millipore (AB775P) Rabbit
Cadherin-11 R&D Systems (AF1433) Goat
Osteocalcin Millipore (AB10911) Rabbit
Osteopontin R&D Systems (AF1790) Goat
iNOS Thermo Scientific (PA1-37924) Rabbit
COX-2 Millipore (AB5118) Rabbit
PGES Sigma (T6079) Rabbit
Secondary
antibodies
Anti-rabbit IgG
(Alexa Fluor-488/546
conjugated)
Invitrogen (A21206/A10040) Donkey
Anti-goat IgG (Alexa
Fluor-546 conjugated)
Invitrogen (A11056) Donkey
Anti-goat IgG
(Biotinylated)
Vector (BA-5000) Rabbit
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Figure S1. Nitric oxide production by cells treated with proinflammatory cytokines,
measured as nitrite accumulation within culture medium. Cells were treated with IL-β, 
TNF-α and IFN-γ for 72 hours at either day 0 (A), day 7 (B), day 14 (C) or day 21 (D) of 
osteogenic culture. Nitrite concentration corrected for DNA content of producing cells
measured by Hoechst assay. Values shown as mean±SEM for three separate experiments each
with n=6. *Statistical significance of primary osteoblast vs. osteo-mESC (p≤0.01) #Statistical
significance vs. control of same cell type (p≤0.01). 
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Figure S2. PGE2 production by cells treated with proinflammatory cytokines. Cells were
treated with IL-β, TNF-α and IFN-γ for 72 hours at either day 0 (A), day 7 (B), day 14 (C) or 
day 21 (D) of osteogenic culture. PGE2 concentration corrected for DNA content of producing
cells measured by Hoechst assay. Values shown as mean±SEM for three separate experiments
each with n=3. *Statistical significance of primary osteoblast vs. osteo-mESC (p≤0.01) 
#Statistical significance vs. control of same cell type (p≤0.01). 
